Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Harvard Business School
Colorcon
McKinsey
Express Scripts

Last Updated: May 27, 2022

Chemo Research Sl Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CHEMO RESEARCH SL, and what generic alternatives to CHEMO RESEARCH SL drugs are available?

CHEMO RESEARCH SL has two approved drugs.

There are seven US patents protecting CHEMO RESEARCH SL drugs.

There are sixteen patent family members on CHEMO RESEARCH SL drugs in nine countries and one supplementary protection certificate in one country.

Summary for Chemo Research Sl
International Patents:16
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Chemo Research Sl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes 8,946,276 See Plans and Pricing See Plans and Pricing
Chemo Research Sl BENZNIDAZOLE benznidazole TABLET;ORAL 209570-001 Aug 29, 2017 RX Yes No See Plans and Pricing See Plans and Pricing
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes 10,238,634 See Plans and Pricing Y See Plans and Pricing
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes 8,658,678 See Plans and Pricing See Plans and Pricing
Chemo Research Sl BENZNIDAZOLE benznidazole TABLET;ORAL 209570-002 Aug 29, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Chemo Research Sl Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0328535 96C0021 Belgium See Plans and Pricing PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
Johnson and Johnson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.